nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adventitious agents, new technology, and risk assessment, 19–20 May 2011, Baltimore, MD
|
Sheets, Rebecca |
|
2012 |
40 |
2 |
p. 162-167 6 p. |
artikel |
2 |
Aims and Scope/Editorial Board/Publishing Details
|
|
|
2012 |
40 |
2 |
p. IFC- 1 p. |
artikel |
3 |
Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in Hepatitis B vaccine manufacturing
|
Milá, Lorely |
|
2012 |
40 |
2 |
p. 118-128 11 p. |
artikel |
4 |
Development and calibration of a standard for the protein content of granulocyte colony-stimulating factor products
|
Gao, Kai |
|
2012 |
40 |
2 |
p. 151-157 7 p. |
artikel |
5 |
Development and qualification of an antibody rapid deglycosylation method
|
Cook, K. Steven |
|
2012 |
40 |
2 |
p. 109-117 9 p. |
artikel |
6 |
Development and validation of an egg-based potency assay for a trivalent live attenuated influenza vaccine
|
Yeolekar, Leena R. |
|
2012 |
40 |
2 |
p. 146-150 5 p. |
artikel |
7 |
Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice
|
Al-Mariri, Ayman |
|
2012 |
40 |
2 |
p. 140-145 6 p. |
artikel |
8 |
International workshop
|
|
|
2012 |
40 |
2 |
p. 168- 1 p. |
artikel |
9 |
Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation
|
Solano, Silvia |
|
2012 |
40 |
2 |
p. 129-133 5 p. |
artikel |
10 |
Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults
|
Palma, Paolo |
|
2012 |
40 |
2 |
p. 134-139 6 p. |
artikel |
11 |
Serological profile of buffalo (Bubalus bubalis) female calves vaccinated with standard Brucella abortus strain 19 vaccine using rose bengal, 2-mercaptoethanol and complement fixation tests
|
Nardi Júnior, G. |
|
2012 |
40 |
2 |
p. 158-161 4 p. |
artikel |